Girish N. Aakalu Ph.D.
Net Worth
Last updated:
What is Girish N. Aakalu Ph.D. net worth?
The estimated net worth of Dr. Girish N. Aakalu Ph.D. is at least $1,613,145 as of 4 Apr 2022. He owns shares worth $45 as insider, has earned $3,840 from insider trading and has received compensation worth at least $1,609,260 in Genocea Biosciences, Inc..
What is the salary of Girish N. Aakalu Ph.D.?
Dr. Girish N. Aakalu Ph.D. salary is $536,420 per year as Chief Bus. Officer in Genocea Biosciences, Inc..
How old is Girish N. Aakalu Ph.D.?
Dr. Girish N. Aakalu Ph.D. is 50 years old, born in 1975.
What stocks does Girish N. Aakalu Ph.D. currently own?
As insider, Dr. Girish N. Aakalu Ph.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Genocea Biosciences, Inc. (GNCA) | Chief Bus. Officer | 74,459 | $0 | $45 |
What does Genocea Biosciences, Inc. do?
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.
Girish N. Aakalu Ph.D. insider trading
Genocea Biosciences, Inc.
Dr. Girish N. Aakalu Ph.D. has made 2 insider trades in 2022, according to the Form 4 filled with the SEC. Most recently he sold 963 units of GNCA stock worth $1,204 on 4 Apr 2022.
The largest trade he's ever made was exercising 2,397 units of GNCA stock on 16 Mar 2022. As of 4 Apr 2022 he still owns at least 74,459 units of GNCA stock.
Genocea Biosciences key executives
Genocea Biosciences, Inc. executives and other stock owners filed with the SEC:
- Dr. Girish N. Aakalu Ph.D. (50) Chief Bus. Officer
- Dr. Thomas A. Davis (61) Chief Medical Officer
- Mr. William D. Clark M.B.A. (56) Pres, Chief Executive Officer & Director